Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Return on Capital Employed (2020 - 2025)

Historic Return on Capital Employed for Foghorn Therapeutics (FHTX) over the last 6 years, with Q3 2025 value amounting to 0.66%.

  • Foghorn Therapeutics' Return on Capital Employed fell 2600.0% to 0.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.66%, marking a year-over-year decrease of 2600.0%. This contributed to the annual value of 0.47% for FY2024, which is 1000.0% down from last year.
  • Per Foghorn Therapeutics' latest filing, its Return on Capital Employed stood at 0.66% for Q3 2025, which was down 2600.0% from 0.56% recorded in Q2 2025.
  • In the past 5 years, Foghorn Therapeutics' Return on Capital Employed registered a high of 0.23% during Q1 2022, and its lowest value of 0.66% during Q3 2025.
  • Its 5-year average for Return on Capital Employed is 0.41%, with a median of 0.42% in 2023.
  • In the last 5 years, Foghorn Therapeutics' Return on Capital Employed soared by 2300bps in 2022 and then plummeted by -2600bps in 2025.
  • Quarter analysis of 5 years shows Foghorn Therapeutics' Return on Capital Employed stood at 0.33% in 2021, then rose by 3bps to 0.32% in 2022, then crashed by -39bps to 0.45% in 2023, then dropped by 0bps to 0.45% in 2024, then tumbled by -48bps to 0.66% in 2025.
  • Its last three reported values are 0.66% in Q3 2025, 0.56% for Q2 2025, and 0.49% during Q1 2025.